Pulse Biosciences (PLSE) Net Cash Flow (2015 - 2025)

Pulse Biosciences has reported Net Cash Flow for 11 years, with the latest figure at -$14.5 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 137.12% year-over-year to -$14.5 million; the trailing twelve-month figure through Dec 2025 stood at -$37.3 million (down 150.63% YoY), and the FY2025 full-year result was -$37.3 million, down 150.63% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$14.5 million, down from -$11.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $54.4 million in Q3 2022, with the low at -$15.9 million in Q1 2022.
• Average Net Cash Flow over 5 years is $3.4 million, with a median of -$7.5 million recorded in 2022.
• Peak annual rise in Net Cash Flow reached 4813.99% in 2021, while the deepest fall reached 348.04% in 2021.
• Tracing PLSE's Net Cash Flow over 5 years: stood at -$13.4 million in 2021, then soared by 40.02% to -$8.0 million in 2022, then rose by 24.95% to -$6.0 million in 2023, then surged by 747.82% to $39.0 million in 2024, then slumped by 137.12% to -$14.5 million in 2025.
• The last three Net Cash Flow figures came in at -$14.5 million (Q4 2025), -$11.1 million (Q3 2025), and -$12.9 million (Q2 2025), per Business Quant data.

Peer Comparison